aPTT in Heparinized Patients: Influence of the Interval Between Sampling and Testing

Abstract

Activated partial thromboplastin times (aPTTs) from 29 whole blood samples were drawn from patients receiv ing unfractionated heparin through a constant intravenous drip. Three aPTTs were determined for each whole blood sample. The first aPTT was performed on a separated portion of the original sample at approximately 30 min from the time of sam pling. A second was performed on the same separated sample at approximately 90 min from the time of sampling, and the third was performed on the original sample at 90 min. The mean aPTT of the set of 30-minute separated samples was 79.7 seconds. The mean aPTT of the 90-minute separated samples was 72.8 seconds. The mean aPTT of the 90-minute original sample was 60.8 seconds. These results demonstrate that an aPTT performed 30 min after sampling yields a value signifi cantly greater than an aPTT performed at 90 min. The lower aPTT values may lead to an unnecessary increase in heparin dosage. This situation underscores the need to further investi gate the aPTT as a foundation for the standardization of the protocol for the use of heparin.

Keywords

Key Words: Activated partial thromboplastin time (aPTT)Bleeding episodes Heparin therapy Sampling time Standardization.

Get full access to this article

View all access options for this article.

References

Scialla S. Heparin monitoring by activated partial thromboplastin time. Am J Clin Pathol 1985;84:351.

Hull RD , Raskob GE , Rosenbloom D. Optimal level of heparin therapy in patients with deep venous thrombosis . Arch Intern Med 1992;152:1589.

Strekerud GE , Abildgaard U. APTT in heparinized plasma: influence of reagent, acute-phase reaction, and interval between sampling and testing . Clin Appl Thrombosis Hemost 1996;2(4):250.

Bjornsson TD , Nash P. Variability in heparin sensitivity of aPTT reagents. Am J Clin Pathol 1986;86:199.

Dahms RA , Wallace J. Heparin sensitivity study using three aPTT reagents on the automated blood coagulation analyzer CA-1000™, Sysmex. J Int 1993;3:160.

Soloway HB , Cox SP , Donahoo JV Sensitivity of the activated partial thromboplastin time to heparin: effect of anticoagulant used for sample collection. Am J Clin Pathol 1973;59:760.

Dade Actin FS activated PTT reagent. Package insert.

Partial thromboplastin time. In: Jacobs DS , Demott WR , Tilzer LL , eds. Laboratory Test Handbook, 3rd ed. Cleveland: Lexi-Comp Inc, 1994.

Hyers TM , Hull RD , Weg JG Antithrombotic therapy for venous thromboembolic disease. Chest 1992;102(suppl):408.

10.

Doyle DJ , Turpie Agg , Hirsh J. Adjusted subcutaneous heparin or continuous intravenous heparin in patients with acute deep venous thrombosis. Ann Intern Med 1987;107:441.

11.

Levine MN , Hirsh J. , Gent M. , et al. A randomized trial comparing activated thromboplastin time with heparin assay in patients with acute venous thromboembolism requiring large daily doses of heparin. Arch Intern Med 1994 ;154:49.

12.

Hull D. , Raskob GE , Hirsh J. Continuous intravenous heparin compared with intermittent subcutaneous heparin in the initial treatment of proximalvein thrombosis. N Engl J Med 1986;315:1109.

13.

Bratt G. , Aberg W. , Johansson M. Two daily subcutaneous injections of Fragmin as compared with intravenous standard heparin in the treatment of deep venous thrombosis. Thromb Haemost 1990; 64:506.

14.

Hirsh J. Heparin. N Engl J Med 1991;324:1565.

15.

Holm HA , Abildgaard U. , Kalvenes S. , et al. The antithrombotic effect of heparin in deep venous thrombosis: relation to four heparin assays. Acta Med Scand 1984;216:287.

16.

Hirsh J. Antithrombotic therapy in deep vein thrombosis and pulmonary embolism . Am Heart J 1992;123:1115.

17.

Hirsh J. , Dalen JE , Deykin D. Heparin: mechanism of action, pharmacokinetics, dosing considerations, monitoring, efficacy and safety. Chest 1992 ;4(suppl):337.

18.

Holm AH , Abildgaard U. , Kalvenes S. Heparin assays and bleeding complications in treatment of deep venous thrombosis with particular reference to retroperitoneal bleeding. Thromb Haemost 1985;55:278.

19.

Salzman EW , Deykin D. , Shapiro RM Management of heparin therapy. N Engl J Med 1975:292:1046.

20.

The Columbus Investigators. Low-molecular-weight heparin in the treatment of patients with venous thromboembolism. N Engl J Med 1997;337:657.

21.

Simonneau G. , Sors H. , Charbonnier B. , et al. A comparison of low-molecular-weight heparin with unfractionated heparin for acute pulmonary embolism. N Engl J Med 1997;337:663.